**ONLINE SUPPLEMENTARY APPENDIX**

**Supplementary Table 1.** Sensitivity analysis of the key variables in the Markov model

|  |  |  |
| --- | --- | --- |
| **Parameter** | **Ranges for 1- way SA** | **Probability distribution** |
| Number of all bleeding episodes per year, on- demand | 8.0-27.0 |  ̴̴ Poisson (17) |
| Number of all bleeding episodes per year, primary prophylaxis | 0.0-9.0 |  ̴̴ Poisson (3) |
| Average cost plasma derived Factor VIII | $90- $1350 | Not applied |
| Average cost recombinant Factor VIII | $145- $2175 | Not applied |
| Utility of being alive without arthopathy, primary prophylaxys or on demand | 0.500- 0.942 | Beta̴ β ̴ (4.426, 0.298) |
| Utility of being alive with arthopathy, primary prophylaxys or on demand | 0.500- 0.883 | Beta̴ β ̴ (3.011, 1.334) |
| Discount rate for costs | 0- 5% | Not applied |
| Discount rate for effects | 0- 5% | Not applied |
| Probability of having an articular bleeding | 0.5- 1.0 | Beta̴ β ̴ (80, 20) |
| Probability of developing arthropathy, on demand | 0.0725- 0.2175 | Beta̴ β ̴ (4.205, 24.795) |
| Probability of developing arthropathy, primary prophylaxis | 0.0094- 0.0282 | Beta̴ β ̴ (0.508, 26.492) |
| Probability of dying from bleeding | 0,0026- 0.0079 | Beta̴ β ̴ (5.618, 1064.383) |

**Supplementary Figure 1.** Tornado diagram (ICER)



**2013 COP per additional QALY**

**Supplementary Figure 2.** Probabilistic Sensitivity Analysis. PP vs. OD ICER scatterplot (WTP 48,458,861 COP)



**Supplementary Figure 3.** Cost-effectiveness acceptability curve

****